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Abstract 
The adrenal glands and sympathetic celiac ganglia are 
innervated mainly by the greater splanchnic nerves, which 
contain preganglionic sympathetic nerves originated from 
thoracic spinal cord. The adrenal medulla has two separate 
populations of chromaffin cells, adrenaline-containing cells (A-
cells) and noradrenaline-containing cells (NA-cells), which have 
been shown to be differentially innervated by separate groups of 
the preganglionic sympathetic neurons. The present study was 
designed to characterize the centrally activating mechanisms of 
the adrenal A-cells, NA-cells and celiac sympathetic ganglia 
with expression of cFos (a marker for neural excitation), in 
regard to the brain prostanoids, in anesthetized rats. 
Intracerebroventricularly (i.c.v.) administered corticotropin-
releasing factor (CRF) induced cFos expression in the adrenal A-
cells, but not NA-cells, and celiac ganglia. On the other hand, 
i.c.v. administered arginine-vasopressin (AVP) resulted in cFos 
induction in both A-cells and NA-cells in the adrenal medulla, 
but not in the celiac ganglia. Intracerebroventricular 
pretreatment with indomethacin (an inhibitor of cyclooxygenase) 
abolished the CRF- and AVP-induced cFos expression in all 
regions described above. On the other hand, 
intracerebroventricular pretreatment with furegrelate (an 
inhibitor of thromboxane A2 synthase) abolished the CRF-induced 
cFos expression in the adrenal A-cells, but not in the celiac 
ganglia, and also abolished the AVP-induced cFos expression in 
both A-cells and NA-cells in the adrenal medulla. These results 
suggest that centrally administered CRF activates adrenal A-
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cells and celiac sympathetic ganglia by brain thromboxane A2-
mediated and other prostanoid than thromboxane A2 (probably 
prostaglandin E2)-mediated mechanisms, respectively. On the other 
hand, centrally administered AVP activates adrenal A-cells and 
NA-cells by brain thromboxane A2-mediated mechanisms in rats. 
 
Key words: Brain arachidonic acid cascade; Brain thromboxane A2; 
cFos expression; Central sympatho-adrenomedullary outflow 
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1. Introduction 
The relative importance of the adrenal medulla and 
sympathetic nervous system in various pathophysiological 
conditions has generally been inferred from measurement of 
plasma adrenaline and noradrenaline, since plasma adrenaline and 
noradrenaline have been shown to reflect the activity of adrenal 
medulla and sympathetic nervous system, respectively. 
Hypoglycemia causes the elevation of plasma adrenaline (Young et 
al., 1984; Fujino and Fujii, 1995; Vollmer et al., 1997), while 
hypotension elevates both catecholamines (noradrenaline > 
adrenaline) (Brown and Fisher, 1984; Vollmer et al., 2000). 
Immobilization stress elicits a robust increase in the plasma 
adrenaline and noradrenaline (Kvetnansky and Mikulaj, 1970; 
Jezova et al., 1999; Dronjak et al., 2004), while cold stress 
triggers a robust increase in plasma noradrenaline (Dronjak et 
al., 2004). Likewise, centrally administered neuropeptides such 
as corticotropin-releasing factor (CRF), arginine-vasopressin 
(AVP), bombesin, thyrotropin-releasing hormone, and •-calcitonin 
gene-related peptide also produce differential changes in the 
plasma catecholamines (Brown et al., 1979, 1985; Fisher et al., 
1983; Brown and Fisher, 1984; Feuerstein et al., 1984; Hasegawa 
et al., 1993; Okuma et al., 1996; Yokotani et al., 2001; Okada 
et al., 2002). 
In the adrenal medulla of both humans and rats, adrenaline 
and noradrenaline are localized in separate populations of cells 
with the number of adrenaline-containing cells (A-cells) about 
4-fold greater than that of noradrenaline-containing cells (NA-
cells) (Verhofstad et al., 1985; Suzuki and Kachi, 1996). 
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Despite the constancy of the stored amounts of adrenaline and 
noradrenaline, the proportion of each catecholamine secreted 
seems to vary depending on the strength and type of stimulus, 
suggesting a differential control of A-cells and NA-cells 
(Vollmer, 1996). Recently, adrenal A- and NA-cells have been 
shown to be innervated by separate groups of preganglionic 
sympathetic neurons located in the spinal cord (Edwards et al., 
1996; Vollmer et al., 2000). Adrenaline secreted into 
circulation is almost produced within the adrenal A-cells 
(Axelrod, 1962; Wurtman, 2002), while plasma noradrenaline seems 
to reflect the secretion from adrenal NA-cells in addition to 
the release from sympathetic nerves (Folkow and von Euler, 1954; 
Vollmer et al., 1997; Yokotani et al., 2001, 2005; Okada et al., 
2003a). However, little is known about centrally controlling 
mechanisms of adrenal A-cells, NA-cells and sympathetic nerves. 
Arachidonic acid is metabolized rapidly to oxygenated 
products, such as prostaglandin E2 and thromboxane A2, by several 
distinct enzymes including cyclooxygenase, prostaglandin E 
synthase and thromboxane A synthase  (Flower and Blackwell, 
1976; Irvine, 1982; Axelrod, 1990). Previously, we reported that 
centrally administered prostaglandin E2 evokes noradrenaline 
release from sympathetic nerves by activation of the brain 
prostanoid EP3 receptors (Yokotani et al., 1995, 2005). Recently 
we also reported that centrally administered CRF evokes the 
brain thromboxane A2-mediated adrenal adrenaline secretion and 
the other prostanoid (probably prostaglandin E2)-mediated 
sympathetic noradrenaline release, while centrally administered 
AVP, bombesin and histamine evoke the brain thromboxane A2-
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mediated adrenal secretion of both adrenaline and noradrenaline 
in rats (Yokotani et al., 2001, 2005; Okada et al., 2003a; 
Shimizu et al., 2006). 
Since the greater splanchnic nerve, which contains 
sympathetic preganglionic nerves originated from spinal cord, 
ramifies into the adrenal gland and celiac sympathetic ganglia 
(Yokotani et al., 1983), these regions are very useful to 
identify the centrally activated adrenal A-, NA-cells and celiac 
sympathetic ganglia with nuclear expression of cFos, immediate 
early gene product (Sagar et al., 1988; Herrera and Robertson, 
1996). In the present study, therefore, we examined the effects 
of centrally administered CRF and AVP on the cFos expression in 
these regions, in regard to the brain arachidonic acid cascade, 
to further clarify the presence of differential activating 
mechanisms for sympathetic nerves and adrenal medulla. 
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2. Materials and methods 
2.1. Animals 
Male Wistar rats weighing about 350 g were maintained in an 
air-conditioned room at 22–24˚C under a constant day–night 
rhythm for more than 2 weeks and given food (laboratory chow, 
CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. All 
effort was made to minimize animal suffering and the number of 
animals used.  All rats were treated in accordance with the 
Guiding Principles for the Care and Use of laboratory animals 
approved by the Graduate School of Medicine, Kochi University. 
 
2.2. Experimental design  
Under urethane anesthesia (1.2 g/kg, i.p.), the animal was 
placed in a stereotaxic apparatus, as shown in our previous 
paper (Yokotani et al., 2001). The skull was drilled for 
intracerebroventricular administration of test substances using 
stainless-steel cannula (0.3 mm outer diameter) or a double 
lumens cannula (0.5 mm outer diameter). The stereotaxic 
coordinates of the tip of cannula were as follows (in mm): AP -
0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from 
the midline; V, below the surface of the brain), according to 
the rat brain atlas (Paxinos and Watson, 1986). Then, 3 h were 
allowed to elapse before the application of test reagents. The 
peptides (CRF and AVP) were slowly injected into the right 
lateral ventricle in a volume of 10 µl using a 10 µl Hamilton 
syringe. CRF and AVP were dissolved in sterile saline. Water-
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soluble indomethacin-Na and furegrelate dissolved in sterile 
saline were also administered into the right lateral ventricle 
in a volume of 10 µl 30 min before the application of CRF or AVP. 
Correct placement of the cannula was confirmed at the end of 
each experiment by verifying that a blue dye, injected through 
the cannula, had spread throughout the entire ventricular system.  
After several periods of time from injection of these peptide 
(CRF and AVP) into the right lateral ventricle (at 0, 10, 60 or 
120 min after injection of CRF; at 0, 10 or 60 min after 
injection of AVP), each rat was perfused through the left 
cardiac ventricle with 100 ml of 0.1 M phosphate buffered saline 
(pH 7.4) followed by 300 ml of ice-cold 4% paraformaldehyde in 
0.1 M phosphate buffer (pH 7.4), as shown in our previous paper 
(Shima et al., 2003).  Then, celiac ganglia around the celiac 
artery and adrenal glands were immediately removed, post-fixed 
over night with the same fixative for the celiac ganglia or with 
3% potassium dichromate and 4% paraformaldehyde in 0.1 M 
phosphate buffer for the adrenal gland with a slight 
modification of the previously reported methods (Coupland et al., 
1964; Piezzi et al., 1983), and then cryoprotected in 20% 
sucrose in 0.1 M phosphate buffer for 24 h at 4˚C. Frozen 
sections (20 µm-thickness) were cut on a cryostat, thaw-mounted 
on silane-coated slides, and then stored at -80˚C until used. 
 
2.3. Immunohistochemistry 
Sections on the slides were washed in phosphate buffered 
saline and then pretreated with 5% normal donkey serum (for 
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adrenal glands) or normal goat serum (for celiac ganglia) in 
phosphate buffered saline containing 0.3% Triton X-100 for 1 h 
at room temperature to eliminate non-specific antibody binding. 
To codetect by double-immunostaining of cFos/phenylethanolamine 
N-methyltransferase (PNMT) in the adrenal medulla or 
cFos/dopamine-β-hydroxylase (DBH) in the celiac ganglia, 
sections were incubated in a cocktail of rabbit anti-cFos 
(1:500) and sheep anti-PNMT (1:200) antibodies for adrenal 
glands, or rabbit anti-cFos (1:500) and mouse anti-DBH (1:500) 
antibodies for celiac ganglia for 4 h at room temperature. After 
incubation, the sections were washed three times for 10 min each 
in phosphate buffered saline, and then incubated for 2 h at room 
temperature in a mixture of secondary antisera; fluorescein 
isothiocyanate-conjugated donkey anti-rabbit IgG (1:200) and 
rhodamine-conjugated donkey anti-sheep IgG (1:200), or 
fluorescein isothiocyanate-conjugated goat anti-rabbit IgG 
(1:200) and rhodamine-conjugated goat anti-mouse IgG (1:200). 
After washing in phosphate buffered saline, nuclei were 
counterstained with 4’,6-diamidine-2’-phenylindole 
dihydrochloride (1:1000) using sections from adrenal glands for 
chromaffin cell counting. After these procedures, the sections 
were coverslipped using mounting medium VECTASHIELD. All 
antisera were diluted in phosphate buffered saline containing 
0.3% Triton X-100 and 10% normal serum produced in the animal 
species from which the respective secondary antibodies were 
obtained. Control experiments were performed by omitting primary 
antibodies as a test of cross-reactivity of secondary antibodies, 
and resulted in the absence of staining. 
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2.4. Image analysis and statistics 
Photomicrographs were captured using a digital camera (DP70, 
Olympus, Tokyo, Japan) attached to a fluorescent microscope 
(AX70, Olympus). The chromaffin reaction method demonstrated 
chromaffin cells with a yellow cytoplasmic staining. In addition, 
immunohistochemical method for PNMT divided chromaffin cells 
into two cell-types, A-cells (PNMT-positive) and NA-cells (PNMT-
negative). Therefore, cFos/PNMT double-staining cells indicate 
activated A-cells, while cFos-staining cells in the PNMT-
negative chromaffin cells indicate activated NA-cells. In the 
celiac ganglia, DBH was used as a marker of noradrenergic 
neurons, and cFos/DBH double-staining indicate activated 
noradrenergic neurons. Quantification of the number of 
immunolabeled cells was carried out within a square of defined 
size (200 x 200 µm) placed on each section of adrenal medulla 
and celiac ganglia. The number of cFos-positive cells, adrenal 
A-cells, NA-cells and ganglionic noradrenergic neurons were 
assessed by cell counting in five sections of each area per 
animal. The percentage of cFos-positive cells in the total A-
cells, NA-cells and ganglionic noradrenergic neurons was 
calculated and expressed as the means ± S.E.M. Data were 
analyzed by one-way analysis of variance, followed by post-hoc 
analysis with the Bonferroni method.  When only two means were 
compared, the data were analyzed by ANOVA followed by unpaired 
Student’s t-test. P values less than 0.05 were taken to indicate 
significance. 
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2.5. Drugs  
The following reagents were used: arginine-vasopressin, 
corticotropin-releasing factor (rat/human) (Peptide Institute, 
Osaka, Japan); •indomethacin sodium trihydrate (a kind gift from 
Merck, Rahway, NJ, U.S.A.); furegrelate sodium (Biomol Research 
Lab., Plymouth Meeting, PA, U.S.A); anti-cFos (Calbiochem, San 
Diego, CA, U.S.A.); anti-dopamine-β-hydroxylase, anti-
phenylethanolamine N-methyltransferase  (Chemicon, Temecula, CA, 
U.S.A.); fluorescein isothiocyanate-conjugated donkey anti-
rabbit IgG, fluorescein isothiocyanate-conjugated goat anti-
rabbit IgG, rhodamine-conjugated donkey anti-sheep IgG, 
rhodamine-conjugated goat anti-mouse IgG  (Jackson 
ImmunoResearch Laboratories, West Grove, PA, U.S.A.); 4’,6-
diamidine-2’-phenylindole dihydrochloride (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD, U.S.A.);  VECTASHIELD (Vector 
Laboratories, Burlingame, CA, U.S.A.). All other reagents were 
the highest grade available (Nacalai Tesque, Kyoto, Japan). 
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3. Results 
3.1. CRF- and AVP-induced cFos expression in the adrenal medulla 
and celiac ganglia 
In the adrenal medulla, A-cells (PNMT-staining cells in the 
total chromaffin cells) were 74.2±5.9% and NA-cells (PNMT-
negative cells in the total chromaffin cells) were 25.8±5.9% 
(n=44). 
Administration of CRF (1.5 and 3.0 nmol/animal, i.c.v.) 
effectively increased cFos expression in the adrenal A-cells and 
noradrenergic neurons in the celiac ganglia, and these responses 
obtained with CRF (1.5 nmol/animal, i.c.v.) was greater than 
those obtained with CRF (3.0 nmol/animal, i.c.v.)  (Fig. 
1A,B,C,D,E,F,K,M). cFos expression in the adrenal A-cells 
gradually increased and reached a maximum 60 min after 
administration of CRF (1.5 and 3.0 nmol/animal) (Fig. 1K,M). In 
noradrenergic neurons in the celiac ganglia, a large dose of CRF 
(3.0 nmol/animal, i.c.v.) quickly evoked cFos expression than a 
small dose of CRF (1.5 nmol/animal, i.c.v.): maximal response 
was obtained at 60 min for CRF (1.5 nmol/animal, i.c.v.) and at 
10 min for CRF (3.0 nmol/animal, i.c.v.), respectively (Fig. 
1K,M). On the other hand, the peptide (1.5 and 3.0 nmol/animal, 
i.c.v.) had no effect on the adrenal NA-cells throughout the 
experimental period (from 0 min to 120 min) (Fig. 1C,E,K,M). 
Administration of AVP (0.2 and 0.5 nmol/animal, i.c.v.) 
effectively increased the levels of cFos expression in the 
adrenal A-cells and NA-cells, and these responses were almost 
the same in both doses of AVP. The maximal cFos expressions in 
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these regions were obtained at 10 min after AVP administration 
(0.2 and 0.5 nmol/animal, i.c.v.) (Fig. 1G,I,L,N). On the other 
hand, the peptide (0.2 and 0.5 nmol/animal, i.c.v.) had no 
effect on noradrenergic neurons in the celiac ganglia throughout 
the experimental period (from 0 min to 60 min) (Fig. 1H,J,L,N). 
In the following experiments, we examined further cFos 
expression at 60 min after the CRF (1.5 nmol/animal, i.c.v.) 
administration and 10 min after the AVP (0.2 nmol/animal, 
i.c.v.) administration, respectively. 
 
3.2. Effects of indomethacin and furegrelate on the CRF-induced 
cFos expression in the adrenal medulla and celiac ganglia 
Sixty min after intracerebroventricular treatments with 
vehicle-1 (10 µl saline) plus vehicle-2 (10 µl saline), 
indomethacin (an inhibitor of cyclooxygenase) [1.2 µmol (500 
µg)/animal] plus vehicle-2, or furegrelate [1.8 µmol (500 
µg)/animal] plus vehicle-2, there were little cFos-positive 
cells in each cell type in the adrenal medulla (A-cells and NA-
cells) and noradrenergic neurons in the celiac ganglia: 
percentage of cFos-positive A-cells in total adrenal A-cells 
[4.2±1.0% for vehicle-1 plus vehicle-2 (n=4), 4.0±0.6% for 
indomethacin plus vehicle-2 (n=3), 5.5±0.3% for furegrelate plus 
vehicle-2 (n=3)]; percentage of cFos-positive NA-cells in total 
adrenal NA-cells [3.9±1.6 for vehicle-1 plus vehicle-2 (n=4), 
3.0±1.0% for indomethacin plus vehicle-2 (n=3), 4.5±0.1% for 
furegrelate plus vehicle-2 (n=3)]; percentage of cFos-positive 
neurons in total noradrenergic neurons in the celiac ganglia 
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[1.1±1.1% for vehicle-1 plus vehicle-2 (n=4), 2.6±0.4% for 
indomethacin plus vehicle-2 (n=3), 1.8±0.4% for furegrelate plus 
vehicle-2 (n=3)] (Fig. 2A,B,I). 
CRF (1.5 nmol/animal, i.c.v.) significantly increased cFos 
expression in the adrenal A-cells and noradrenergic neurons in 
the celiac ganglia, but had no effect on the adrenal NA-cells: 
percentage of cFos-positive cells in total cells in each group 
[A-cells, 32.4±1.1%; NA-cells, 2.1±2.1%; noradrenergic neurons 
in the celiac ganglia, 48.5±6.4% (n=4)] (Fig. 2C,D,I). 
Pretreatment with indomethacin (1.2 µmol/animal, i.c.v.) 
abolished the CRF (1.5 nmol/animal, i.c.v.)-induced cFos 
expression in all regions (adrenal A-cells and noradrenergic 
neurons in the celiac ganglia): percentage of cFos-positive 
cells in total cells in each group [A-cells, 3.9±1.1%; NA-cells, 
3.3±1.7%; noradrenergic neurons in the celiac ganglia, 6.1±4.6 
(n=4)] (Fig. 2E,F,I). 
Pretreatment with furegrelate (1.8 µmol/animal, i.c.v.) 
abolished the CRF-induced cFos expression in the adrenal A-cells, 
but had no effect on the noradrenergic neurons in the celiac 
ganglia: percentage of cFos-positive cells in total cells in 
each group [A-cells, 5.1±2.2%; NA-cells, 4.8±3.3%; noradrenergic 
neurons in the celiac ganglia, 41.4±8.6% (n=4)] (Fig. 2G,H,I). 
 
3.3. Effects of indomethacin and furegrelate on the AVP-induced 
cFos expression in the adrenal medulla and celiac ganglia 
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Ten min after intracerebroventricular treatments with 
vehicle-1 (10 µl saline) plus vehicle-2 (10 µl saline), 
indomethacin (an inhibitor of cyclooxygenase) [1.2 µmol (500 
µg)/animal] plus vehicle-2, or furegrelate [1.8 µmol (500 
µg)/animal] plus vehicle-2, there were little cFos-positive 
cells in each cell type in the adrenal medulla (A-cells and NA-
cells) and noradrenergic neurons in the celiac ganglia: 
percentage of cFos-positive cells in total A-cells [3.5±0.9% for 
vehicle-1 plus vehicle-2 (n=4), 5.6±1.4% for indomethacin plus 
vehicle-2 (n=3), 4.1±1.4% for furegrelate plus vehicle-2 (n=3)];  
percentage of cFos-positive cells in total NA-cells [5.0±0.7% 
for vehicle-1 plus vehicle-2 (n=4), 4.7±0.9% for indomethacin 
plus vehicle-2 (n=3), 4.0±1.2% for furegrelate plus vehicle-2 
(n=3)]; percentage of cFos-positive cells in total noradrenergic 
neurons in the celiac ganglia [2.5±1.0% for vehicle-1 plus 
vehicle-2 (n=4), 2.5±0.6% for indomethacin plus vehicle-2 (n=3), 
3.8±0.8 for furegrelate plus vehicle-2 (n=3)] (Fig. 3A,B,I). 
AVP (0.2 nmol/animal, i.c.v.) significantly increased cFos 
expression in the adrenal A-cells and NA-cells, but had no 
effect on the noradrenergic neurons in the celiac ganglia: 
percentage of cFos-positive cells in total cells in each group 
[A-cells, 37.2±1.0%; NA-cells, 40.2±5.8%; noradrenergic neurons 
in the celiac ganglia, 2.0±1.0% (n=4)] (Fig. 3C, D and I). 
Indomethacin [1.2 µmol (500 µg)/animal, i.c.v.] abolished the 
AVP (0.2 nmol/animal)-induced cFos expression in all regions 
(the adrenal A-cells and NA-cells): percentage of cFos-positive 
cells in total cells in each group [A-cells, 5.3±0.8%; NA-cells, 
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6.2±3.1%; noradrenergic neurons in the celiac ganglia, 3.2±3.2% 
(n=4)] (Fig. 3E,F,I). 
Furegrelate [1.8 µmol (500 µg)/animal, i.c.v.] also abolished 
the AVP-induced cFos expression in all regions such as the 
adrenal A-cells and NA-cells: percentage of cFos-positive cells 
in total cells in each group [A-cells, 7.9±3.2%; NA-cells, 
3.4±2.7%; noradrenergic neurons in the celiac ganglia, 1.1±1.1% 
(n=4)] (Fig. 3G,H,I). 
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4. Discussion 
In many mammalian species, adrenomedullary chromaffin cells 
consist of A-cells and NA-cells. The former cells contain the 
enzyme PNMT, which converts noradrenaline to adrenaline. 
Previous studies with immunohistochemical staining for PNMT show 
that A-cells occupied large areas in the adrenal medulla, and 
NA-cells were scattered among A-cell regions  (Edwards et al., 
1996; Suzuki and Kachi, 1996; Phillips et al., 2001). In the 
present experiment, the number of A-cells is about 3-fold 
greater than that of NA-cells in the rat adrenal medulla. In the 
celiac ganglia around the celiac artery, there are many 
noradrenergic neurons containing the enzyme DBH, which converts 
dopamine to noradrenaline. In the present experiment, we used 
cFos expression as an indicator of neuronal and cellular 
activity. Although the DBH and the PNMT promoter regions do not 
contain an AP-1 site (Ebert et al., 1994; Morita et al., 1995; 
Sabban and Kvetnansky, 2001), suggesting that direct effects of 
cFos on the synthesis of these enzymes are unlikely, tyrosine 
hydroxylase (a rate-limiting enzyme in catecholamine synthesis) 
contains an AP-1 site in its promotor region (Chambi et al., 
1989; Liu et al., 1997). Many previous studies have shown the 
colocalization of cFos and PNMT immunoreactivities to prove the 
neural activity in the adrenergic neuron in the brain (Jung et 
al., 2004; Lee et al., 2000; Ritter et al., 1998; Temel et al., 
2002; Yang and Voogt, 2001).  
Previously we reported that centrally administered CRF (0.5, 
1.5 and 3.0 nmol/animal) and AVP (0.1, 0.2 and 0.5 nmol/animal) 
dose-dependently elevated plasma levels of noradrenaline and 
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adrenaline in anesthetized rats (Yokotani et al., 2001; Okada et 
al., 2002). In the first experiment, we examined the time course 
of cFos induction in the adrenal A- and NA-cells and 
noradrenergic neurons in the celiac ganglia in response to 
centrally administered CRF (1.5 and 3.0 nmol/animal) or AVP (0.2 
and 0.5 nmol/animal). CRF effectively induced cFos expression in 
the adrenal A-cells and noradrenergic neurons in the celiac 
ganglia, although CRF even at a higher dose had no effect on the 
adrenal NA-cells throughout the experimental period (120 min). 
AVP also effectively induced cFos expression in both A- and NA-
cells in the adrenal medulla, however AVP even at a higher dose 
had no effect on noradrenergic neurons in the celiac ganglia 
throughout the experimental period (60 min). Intravenous 
administration of these peptides had no effect on cFos 
expression in any regions. These results suggest that centrally 
administered CRF activates adrenal A-cells and celiac 
sympathetic ganglia, while centrally administered AVP activates 
both the adrenal A-cells and NA-cells in rats. These results are 
well consistent with our previous paper in which bilateral 
adrenalectomy abolished the AVP-induced elevations of plasma 
noradrenaline and adrenaline, while the procedure abolished only 
the CRF-induced elevation of plasma adrenaline in rats (Okada et 
al., 2003a). The differences in the time course of cFos 
expression between CRF- and AVP-treated rats may be, in part, 
due to the differences in their signal transductions in the 
brain. We previously reported the involvement of brain inducible 
nitric oxide synthase in the centrally administered CRF-induced 
increase of plasma catecholamines (Okada et al., 2003b). Brain 
nitric oxide has been shown to activate the brain cyclooxygenase, 
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thereby elevating plasma catecholamines in rats (Murakami et al., 
1998). 
In the second experiments, we examined the effects of 
indomethacin, a non-selective inhibitor of cyclooxygenase (Insel, 
1996), on the centrally administered CRF- and AVP-induced cFos 
expression. The central pretreatment with indomethacin abolished 
the CRF-induced all cFos expression in the adrenal A-cells and 
noradrenergic neurons in the celiac ganglia and also abolished 
the AVP-induced all cFos expression in the adrenal A-cells and 
NA-cells. These results suggest the involvement of the brain 
arachidonic acid cascade in the CRF- and AVP-induced responses. 
The present results are well consistent with those of our 
previous report in which central pretreatment with indomethacin 
abolished the centrally administered CRF- and AVP-induced 
elevation of plasma catecholamines in rats (Yokotani et al., 
2001; Okada et al., 2003a). 
Finally, we examined the effects of furegrelate, a selective 
inhibitor of thromboxane A2 synthase (Gorman et al., 1983), on 
the centrally administered CRF- and AVP-induced cFos expression. 
Central pretreatment with furegrelate abolished the CRF-induced 
cFos expression in the adrenal A-cells (but not noradrenergic 
neurons in the celiac ganglia), and also abolished the AVP-
induced all cFos expression in the adrenal A-cells and NA-cells. 
These results indicate the involvement of brain thromboxane A2 
in the centrally administered CRF-mediated activation of adrenal 
A-cells and AVP-mediated activation of adrenal A- and NA-cells 
in rats. The present results are well consistent with our 
previous paper, in which the central pretreatment with 
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furegrelate abolished the CRF-induced elevation of adrenaline 
(but not noradrenaline) and the AVP-induced elevations of both 
adrenaline and noradrenaline in rats (Yokotani et al., 2001; 
Okada et al., 2003a). 
A question has arisen which type of prostanoids is involved 
in the centrally administered CRF-induced cFos expression in the 
noradrenergic neurons in the celiac ganglia.  In previous 
studies, we reported that centrally administered prostaglandin 
E2 (but not prostaglandin D2, prostaglandin F2 or prostaglandin 
I2) elevated plasma levels of noradrenaline alone by activation 
of the brain prostanoid EP3 receptors in rats (Yokotani et al., 
1995; Murakami et al., 2002) and this elevation was not 
influenced by bilateral adrenalectomy (Yokotani et al., 2005). 
These results suggest the involvement of brain prostaglandin E2 
in the centrally administered CRF-induced cFos expression in the 
noradrenergic neurons in the celiac ganglia. 
The hypothalamus, especially the paraventricular nucleus, has 
been considered to be the control center of the sympatho-
adrenomedullary outflow (Swanson and Sawchenko, 1980). 
Retrograde tracer studies suggest a possible connection between 
the sympatho-adrenomedullary system and the paraventricular 
nucleus through the splanchnic nerve and spinal cord (Luiten et 
al., 1987; Jansen et al., 1995; Ranson et al., 1998). Recently 
we reported that N-methyl-D-aspartate applied into the rat 
paraventricular nucleus using microdialysis technique produced 
thromboxane A2 release in this region and elevation of plasma 
catecholamines in rats (Okada et al., 2000). Microinjection of 
thromboxane A2 mimetic into the rat paraventricular nucleus 
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elevated plasma catecholamines (Murakami et al., 2002). Further 
immunohistochemical studies are required to clarify the brain 
regions involved in the CRF- or AVP-induced activation of 
sympatho-adrenomedullary outflow in rats.  
In summary, we demonstrated here that centrally administered 
CRF activates adrenal A-cells and noradrenergic neurons in the 
celiac ganglia by the brain thromboxane A2-mediated and the 
other prostanoid than thromboxane A2 (probably prostaglandin E2)-
mediated mechanisms, respectively. On the other hand, centrally 
administered AVP activates adrenal A-cells and NA-cells by brain 
thromboxane A2-mediated mechanisms in rats. 
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Legends to figures 
Fig. 1. CRF- and AVP-induced cFos expression in the adrenal 
medulla and celiac ganglia. CRF (1.5 and 3.0 nmol/animal, 
i.c.v.) or AVP (0.2 and 0.5 nmol/animal, i.c.v.) was 
administered in anesthetized rats. cFos expression in the 
adrenal medulla (A,C,E,G,I) and celiac ganglia (B,D,F,H,J) was 
examined at 0 min (A,B) and 60 min (C,D) after CRF (1.5 
nmol/animal) administration and at 120 min (E,F) after CRF (3.0 
nmol/animal)  administration, or 0 min (A,B) and 10 min (G,H) 
after AVP (0.2 nmol/animal) administration and at 60 min (I,J) 
after AVP (0.5 nmol/animal) administration. In the adrenal 
medulla, cFos is shown in the left panel, PNMT is shown in the 
middle panel and both in the right panel.  In the celiac ganglia, 
cFos is shown in the left panel, DBH is shown in the middle 
panel and both in the right panel. Scale bar = 100 µm. (K-N) 
Quantitative analysis of the percentage of cFos-positive cells 
in all cells in each group (adrenal A-cells and NA-cells and 
noradrenergic neurons in the celiac ganglia) after 
intracerebroventricular administration of CRF (1.5 nmol/animal, 
K; 3.0 nmol/animal, M) or AVP (0.2 nmol/animal, L; 0.5 
nmol/animal, N). ■ , adernal A cells; ● , adrenal NA cells; ▲ , 
celiac ganglia. Results represent the means±S.E.M. (n=4 in each 
group). #Significantly different (P<0.05) from 0 min before 
intracerebroventricular administration of CRF or AVP with the 
Bonferroni method. 
Fig. 2. Effects of indomethacin and furegrelate on the CRF-
induced cFos expression in the adrenal medulla and celiac 
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ganglia. Indomethacin (IND)  [1.2 µmol (500 µg)/animal], 
furegrelate [1.8 µmol (500 µg)/animal] (FUR) or vehicle-1 (10 µl 
saline) was administered 30 min before application of CRF (1.5 
nmol/animal, i.c.v.) or vehicle-2 (10 µl saline, i.c.v.). cFos 
expression in the adrenal medulla (A,C,E,G) and celiac ganglia 
(B,D,F,H) was examined 60 after CRF (or vehicle-2) 
administration. (A,B) vehicle-1 plus vehicle-2; (C,D) vehicle-1 
plus CRF; (E,F) indomethacin (IND) plus CRF; (G,H) furegrelate 
(FUR) plus CRF. (I) Quantitative analysis of the percentage of 
cFos-positive cells in all cells in each group (adrenal A-cells 
and NA-cells and noradrenergic neurons in the celiac ganglia) 
after intracerebroventricular administration of CRF (n=4 in each 
group). Other conditions were the same as those in Fig. 1. 
*Significantly different (P<0.05) from the group treated with 
vehicle-1 plus vehicle-2 with the Student’s t-test; 
#significantly different (P<0.05) from the group treated with 
vehicle-1 plus CRF with the Bonferroni method. 
 
Fig. 3. Effects of indomethacin and furegrelate on the AVP-
induced cFos expression in the adrenal medulla and celiac 
ganglia. Indomethacin (IND)  [1.2 µmol (500 µg)/animal], 
furegrelate [1.8 µmol (500 µg)/animal] (FUR) or vehicle-1 (10 µl 
saline) was i.c.v. administered 30 min before the application of 
AVP (0.2 nmol/animal) or vehicle-2 (10 µl saline). cFos 
expression in the adrenal medulla (A,C,E,G) and celiac ganglia 
(B,D,F,H) was examined 10 min after AVP (or vehicle-2) 
administration. (A,B) vehicle-1 plus vehicle-2; (C,D) vehicle-1 
plus AVP; (E,F) indomethacin (IND) plus AVP; (G,H) furegrelate 
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(FUR) plus AVP. (I) Quantitative analysis of the percentage of 
cFos-positive cells in all cells in each group (adrenal A-cells 
and NA-cells and noradrenergic neurons in the celiac ganglia) 
after intracerebroventricular administration of AVP (n=4 in each 
group). Other conditions were the same as those in Figs. 1 and 2. 
*Significantly different (P<0.05) from the group treated with 
vehicle-1 plus vehicle-2 with the Student’s t-test; 
#significantly different (P<0.05) from the group treated with 
vehicle-1 plus CRF with the Bonferroni method.  
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